Tyrosine hydroxylase catalyses the hydroxylation of
L-tyrosine to
l-DOPA, the rate-limiting step in the synthesis of
catecholamines. Mutations in the TH gene encoding
tyrosine hydroxylase are associated with the autosomal recessive disorder
tyrosine hydroxylase deficiency, which manifests phenotypes varying from infantile
parkinsonism and
DOPA-responsive dystonia, also termed type A, to complex
encephalopathy with perinatal onset, termed type B. We generated homozygous Th knock-in mice with the mutation Th-p.R203H, equivalent to the most recurrent human mutation associated with type B
tyrosine hydroxylase deficiency (TH-p.R233H), often unresponsive to
l-DOPA treatment. The Th knock-in mice showed normal survival and food intake, but
hypotension,
hypokinesia, reduced motor coordination, wide-based gate and
catalepsy. This phenotype was associated with a gradual loss of central
catecholamines and the serious manifestations of motor impairment presented diurnal fluctuation but did not improve with standard
l-DOPA treatment. The mutant
tyrosine hydroxylase enzyme was unstable and exhibited deficient stabilization by
catecholamines, leading to decline of brain
tyrosine hydroxylase-immunoreactivity in the Th knock-in mice. In fact the substantia nigra presented an almost normal level of mutant
tyrosine hydroxylase protein but distinct absence of the
enzyme was observed in the striatum, indicating a mutation-associated mislocalization of
tyrosine hydroxylase in the nigrostriatal pathway. This hypomorphic mouse model thus provides understanding on pathomechanisms in type B
tyrosine hydroxylase deficiency and a platform for the evaluation of novel
therapeutics for
movement disorders with loss of dopaminergic input to the striatum.